Pricing Log in Create free account

Incyte Corporation (INCY) vs Revolution Medicines, Inc. (RVMD)

Incyte Corporation and Revolution Medicines, Inc. are both Biotechnology companies. Revolution Medicines, Inc. is the larger, with a market value of $38.1B against $24.1B — 1.6× the size. Revolution Medicines, Inc. has negative trailing earnings, so its P/E is not meaningful; Incyte Corporation trades at 56.3×. Revolution Medicines, Inc. grew revenue faster over the last twelve months: 491.1% against 24.9%. Incyte Corporation has the higher net margin (6.71% vs −894.4%) and the higher return on invested capital (21.6% vs 0.00%). Across the 18 metrics below, Incyte Corporation leads on 14 and Revolution Medicines, Inc. on 4.

Valuation

Metric INCY RVMD Biotechnology median
P/E 56.33 n/m 10.26
P/S 4.00 184.79 9.18
P/B 4.26 16.09 2.05
Price to free cash flow 35.34 n/m 24.81
EV/EBITDA 27.88 n/m 0.65
EV/Sales 3.36 172.29 8.98
Earnings yield 1.78% (5.07%) (34.89%)
Free cash flow yield 2.83% (3.73%) (24.52%)

Profitability

Metric INCY RVMD Biotechnology median
Gross margin 92.69% 95.62% 65.16%
Operating margin 10.42% (805.75%) 0.00%
Net margin 6.71% (894.40%) 0.00%
Free cash flow margin 11.31% (688.93%) 0.00%
Return on equity 7.84% (93.56%) (50.12%)
Return on assets 5.92% (57.07%) (45.60%)
Return on invested capital 21.56% 0.00% 0.00%

Growth

Metric INCY RVMD Biotechnology median
Revenue growth (TTM) 24.88% 491.12% 6.26%
EPS growth (last fiscal year) 4,173.33% (66.20%) 29.88%
Revenue growth, 5-year CAGR 14.03% (10.50%) 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric INCY RVMD Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.84 8.36 4.89
Net debt to EBITDA (2.21) 1.47 1.01

Dividend

Metric INCY RVMD Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric INCY RVMD Biotechnology median
Market cap 24.05b 38.08b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack